Knight Therapeutics Inc.
GUD.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.60% | 8.76% | 11.36% | 2.95% | 2.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.60% | 8.76% | 11.36% | 2.95% | 2.39% |
| Cost of Revenue | 22.16% | 11.19% | 10.32% | -0.86% | -4.65% |
| Gross Profit | -1.74% | 5.95% | 12.55% | 7.38% | 11.16% |
| SG&A Expenses | 16.39% | 13.75% | 16.84% | 2.96% | -1.06% |
| Depreciation & Amortization | -9.53% | -6.82% | -2.98% | -12.91% | -13.83% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.85% | 10.03% | 11.26% | -0.86% | -4.07% |
| Operating Income | -206.56% | -113.47% | 16.46% | 484.56% | 157.35% |
| Income Before Tax | 68.39% | 135.62% | 108.04% | -69.34% | 12.69% |
| Income Tax Expenses | -204.87% | 69.58% | 56.84% | 88.65% | 78.00% |
| Earnings from Continuing Operations | 100.84% | 161.52% | 123.95% | -305.02% | -34.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 100.84% | 161.52% | 123.95% | -305.02% | -34.85% |
| EBIT | -206.56% | -113.47% | 16.46% | 484.56% | 157.35% |
| EBITDA | -33.71% | -8.28% | 3.79% | 9.58% | 29.21% |
| EPS Basic | 100.39% | 162.16% | 124.96% | -421.67% | -54.56% |
| Normalized Basic EPS | -54.76% | 18.63% | 45.85% | 15.00% | 15,650.00% |
| EPS Diluted | 95.02% | 155.29% | 119.40% | -388.40% | -49.10% |
| Normalized Diluted EPS | -55.24% | 18.15% | 45.40% | 15.00% | 15,650.00% |
| Average Basic Shares Outstanding | -2.80% | -4.05% | -6.00% | -8.06% | -8.60% |
| Average Diluted Shares Outstanding | -2.65% | -3.95% | -6.01% | -8.16% | -8.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |